SRES 97
113th Congress
Senate
Health
Drug safety, medical device, and laboratory regulation
Drug, alcohol, tobacco use
Prescription drugs
A resolution expressing the sense of the Senate that the Food and Drug Administration should encourage the use of abuse-deterrent formulations of drugs.
Introduced: April 15, 2013
See on congress.gov
Everywhere this bill has been
2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Apr 15, 2013
Referred to the Committee on Health, Education, Labor, and Pensions. (text of measure as introduced: CR S2654)
Apr 15, 2013
Introduced in Senate
Plain-English summary
Expresses the sense of the Senate that the Food and Drug Administration (FDA) should exercise its acknowledged authority to: (1) refuse to approve generic versions of non-abuse-deterrent opioid products that have been replaced in the market with abuse-deterrent formulations recognized by FDA as effective, and (2) require generic versions of abuse-deterrent opioid products to be formulated with comparable abuse-deterrent features.
What's happening now
Referred to the Committee on Health, Education, Labor, and Pensions. (text of measure as introduced: CR S2654)
Committees of jurisdiction
1